Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

Amarillo Biosciences And CytoPharm Announce Start Of Enrollment For Hepatitis C Study In Taiwan
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) and CytoPharm, Inc. today jointly announced the start of enrollment for a study of ABI"s oral interferon-alpha lozenges for chronic hepatitis C virus infection. The aim of the trial is to reduce the virologic relapse rate for those patients who have completed the standard combination therapy, which consists of high dose injectable interferon-alpha and Ribavirin. Although most patients respond to the standard therapy, up to 50% of those with certain "high-risk" viral genotypes relapse after treatment.
pharmacy online
Fingolimod And Cladribine: Two New Oral Substances Show Promising Results In Current Clinical Trials For MS Therapy
The results of current clinical trials on new substances for MS therapy are among the new research findings that are being discussed with particular interest at the ENS meeting. Professor Comi is part of an international research team presenting the latest results of a study involving the orally administered drug fingolimod that is still in the clinical trial state and yet to be approved. An earlier study showed that oral fingolimod reduced the annualizied relapse rate in MS patients by more than 50 percent versus placebo.
News of the day
Why African Americans Are At Greater Risk Of Hypertension And Kidney Disease
Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center believe that a heightened level a certain growth factor in the blood may explain why blacks have a greater prevalence of hypertension and kidney disease compared to whites. Results from a new study are the first to show that an elevated level of a protein, called transforming growth factor b1 (TGF-b1), raises the risk of hypertension and renal disease in humans.
Public Health

Response To Intracerebral Haemorrhage Study In The Lancet

Doctor David Werring, from The Stroke Association"s Expert Advisory Panel said: "Non-traumatic intracerebral haemorrhage is a major cause of death and disability which is becoming more common, in part because of the increasing use of anticoagulants and antiplatelet agents in older people who may have fragile blood vessels in the brain. More research is urgently needed to better understand the underlying causes of blood vessel damage and to try to prevent some intracerebral haemorrhages by controlling blood pressure and avoiding antithrombotic drugs in people identified to be at highest bleeding risk. However, people who have been prescribed anticoagulants and antiplatelet medications should continue taking these unless instructed otherwise by their doctor." The Stroke Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009